ReviewFrontiers in pharmacology2024
The double-edged nature of nicotine: toxicities and therapeutic potentials.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Forensic Perspective of Unintentional Doping, Cardiovascular Health, and the Role of Nutrition in Competitive Sports.Nutrients · 2026Pooled it
- Toxicological and pharmacodynamic evaluation of Nixodine-S [(S)-6-Methylnicotine] relative to (S)-nicotine.Toxicology reports · 2026Article
- Toxic Plants Potentially Impacting the Health Status of Livestock in St. Kitts-A Surveillance Study.Toxins · 2026Article
- Effects of cigarette smoke and HIV-1 factors on blood-brain barrier integrity and permeability in an in vitro model.Journal of neurovirology · 2026Article
- Alpha-7 nicotinic acetylcholine receptor: targeting the interplay between inflammation, renin-angiotensin aldosterone system, and nervous system for the novel treatment of heart failure.Frontiers in pharmacology · 2026Review
- Smoking accelerates immunosenescence in multiple sclerosis.Frontiers in immunology · 2026Review
- Nicotinic Acetylcholine Receptor Pathways in Cancer: From Psychiatric Clues to Therapeutic Opportunities.Cancer reports (Hoboken, N.J.) · 2025Review
- A Narrative Review on the Role of Microbiota and Microglia in Premotor Symptoms of Parkinson's Disease.Neurotoxicity research · 2025Review
- Nicotine from a Different Angle: Biological Effects from a Psychoneuroimmunological Perspective.International journal of molecular sciences · 2025Review
- A comprehensive assessment of smokeless tobacco (Shammah) extract: unraveling the effects on hematological parameters, antioxidant defense mechanisms, and organ health in rats.Journal of molecular histology · 2025Article
- Behavioral and neurochemical alterations induced by long-term exposure to tobacco heating system emissions in rats.Frontiers in pharmacology · 2025Article
- Opinion: exploring alternative pathways to neuroprotection-nicotine and carbon monoxide as antioxidative factors in neurodegeneration and delirium.Frontiers in neurology · 2025Article
- Review
- Nicotine's impact on platelet function: insights into hemostasis mechanisms.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nicotine is the primary addictive component of cigarette smoke and is associated with various smoking-related diseases. However, recent research has revealed its broader cognitive-enhancing and anti-inflammatory properties, suggesting its potential therapeutic applications in several conditions. This review aims to examine the double-edged nature of nicotine, encompassing its positive and negative effects. We provide a concise overview of the physiochemical properties and pharmacology of nicotine, including insights into nicotine receptors. Therefore, the article is divided into two main sections: toxicity and therapeutic potential. We comprehensively explored nicotine-related diseases, focusing on specific signaling pathways and the underlying mechanisms that contribute to its effects. Furthermore, we addressed the current research challenges and future development perspectives. This review aims to inspire future researchers to explore the full medical potential of nicotine, which holds significant promise for the clinical management of specific diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.